Pancreatic islet transplantation into type 1 diabetic patients is currently being performed by intraportal infusion. This method, albeit reproducible, has some disadvantages including potential development of portal hypertension, hemorrhage, and an inability to retrieve or detect the transplanted tissue. Other transplant sites have been examined in animal models including the omentum, peritoneal cavity, and the spleen. A transplant site that has not been successful in supporting functional islet tissue transplantation in humans is the subcutaneous space due primarily to the lack of a well-defined vascular bed. This site has many favorable characteristics such as ease of access for transplantation and potential for removal of the transplanted tissue with a minimally invasive surgical procedure. This report addresses the evaluation of a subcutaneously placed device for the support of rat syngeneic islet transplantation in a streptozocin-induced diabetic model. The data generated support the use of this device for islet engraftment. In addition, beta cell function in this device compared favorably with the function of islets transplanted to the renal subcapsular space as well as islets within the native pancreas.
INTRODUCTION
engraftment of a large mass of transplanted tissue. Nevertheless, some success using this site for transplantation was demonstrated by Scharp et al. when they reported Several groups have recently succeeded in rendering patients with type 1 diabetes insulin independent after 2-week survival of human allogeneic islets embedded in an alginate matrix immobilized within a hollow fiber infusion of allogeneic islets into the portal circulation (19, 20, 23, 24) . While this has been encouraging, signifi-membrane (22) . Due to the small number of islets that were implanted in these studies, no functional outcome cant safety concerns are associated with the surgical procedures and the method/site of transplantation remains was expected or detected. In addition, while islet survival was reported, central necrosis was evident within to be optimized (20) . For instance, intraportal infusion is associated with a risk of intra-abdominal bleeding and some of the larger islets due to the lack of direct integration of the grafted cells with the surrounding vascula-portal vein thrombosis. In addition, intraportal transplantation does not discretely localize the grafted islets and ture. These data suggest that the subcutaneous space might thus they are not accessible for either imaging or biopsy. Given these considerations, other more readily accessi-be a useful transplant site if a vascular bed suitable for engraftment of a substantial islet mass can be estab-ble transplant sites, such as the omental pouch and subcutaneous space, have been explored (1,6,10,12,14, 18, lished prior to the actual transplant. Normally, the subcutaneous space consists of adipocytes, hair follicles, 22, 25, 27) .
The subcutaneous space is a particularly appealing macrophages, fibroblasts, and a loosely dispersed capillary bed. The poor vascularization of the subcutaneous transplant site for several reasons, including its ease of accessibility by minimally invasive techniques for both space does not support the engraftment of highly metabolic cells like islets. Indeed, this environment is in di-graft implantation and explantation. It is, however, a relatively hypovascular space that cannot normally support rect contrast to the native pancreas where approximately 10% of the volumetric blood flow of the pancreas is Device Design associated with the islets (9). This blood flow is required
The chambers used for the subcutaneous islet grafts for metabolic requirements, and also to ensure quick de-( Fig. 1) were manufactured from #40 stainless steel tection of blood glucose levels and concomitant secremesh with a wire diameter of 0.010 in. and with 36% of tion of either insulin or glucagon. Accordingly, success-
the mesh being open (Kineteks, Inc., North Kingston, ful islet grafting into the subcutaneous site will require RI). The mesh forms a network of squares with an openthe establishment and maintenance of a three-dimening width of 0.15 in. and each square inch contained 40 × sional vascular bed that can support islet engraftment 40 mesh squares. The wire mesh was rolled into a cylindand function.
rical configuration and laser-welded along its length to To date, most of the published attempts at creating a achieve a uniform seal. The external diameter of the vascular bed for islet grafts have focused on concurrent chambers was 5.5 mm. One end of the chamber was delivery of growth factors in combination with biomatefitted with a permanent Teflon plug extending 4 mm rials (11, 17, 21, 27) or biomaterials without growth facinto the device and 2.7 mm externally from the end of tors (10,14,25). Most of these studies have been perthe device. The other end of the device was fitted with formed in mice and have required a small volume of a removable Teflon obdurator that when placed into the islets for transplantation. Recently, however, Valdes and device, abutted against the Teflon plug at the opposite colleagues, in a controversial report, described successend of the chamber. The obdurator was approximately 3 ful transplantation of porcine islets into a stainless steel mm in diameter, allowing slightly more than 1 mm of chamber that was prevascularized by placement in the free space along the outer edges of the stainless steel subcutaneous space (abdomen) of diabetic children mesh to be infiltrated with tissue. The external portion weeks prior to islet transplantation (26) . Although it is of the obdurator extended approximately 5.3 mm from unclear that such a device is immunoprotective for xenothe device and was fitted into the device and removed geneic tissue, it may engender the creation of a vascular with minimal effort. The resulting configuration allowed bed for the subcutaneous transplantation of islets. Here approximately 48 mm in length of hollow space for subwe report an initial examination of the suitability of a sequent cell placement. All components were autoclaved similar device placed in the subcutaneous space of diaprior to surgery. betic rats. Using a stepwise approach we determined Device Implantation whether the local environment created by these chambers is capable of supporting syngeneic islet grafts in The devices were transplanted into the subcutaneous rats. Specifically, we allowed a cylindrical stainless steel space on the dorsal aspect of the animal. The animal mesh chamber to engraft for a period of time within the was anesthetized with inhalation isoflurane (2%) and the subcutaneous space prior to the placement of islets intransplant site was prepared for surgery using a Betadside the device. We then confirmed islet survival, funcine/alcohol scrub. A 3-mm incision was made through tion, and normoglycemia in recipient diabetic rats. These which a subcutaneous pocket approximately 5 cm in studies demonstrate that this device allows a minimally length was created by blunt dissection. The device, with invasive method of islet transplantation that cannot oththe obdurator and cap in place, was slipped into the suberwise be achieved within the subcutaneous space. The cutaneous space and the incision was closed with 5-0 device can be easily manipulated to adjust the conditions Polysorb (Cardinal Health, Dublin, OH). for islet cells prior to transplantation and is suitable for Diabetic Induction multiple, sequential transplants.
Approximately 60 days after device implantation rats MATERIALS AND METHODS were rendered diabetic via a tail vein injection of strep-Animals tozotocin (0.7 ml of 0.016 g/ml; Sigma, St. Louis, MO).
Male Lewis rats (Harlan-Sprague Dawley, Indianapo-
Once an animal exhibited a nonfasting glucose level of lis, IN) were used as islet donors and female Lewis rats 350 mg/dl on 2 consecutive days, it was considered dia-(Harlan-Sprague Dawley) were used as recipients. Anibetic and suitable for islet transplantation. mals had free access to water and pelleted rat food Islet Isolation and Culture throughout the course of the study, with the exception of the fasting of donor rats the night prior to the removal Pancreatic islets were prepared by distending the pancreas with an intraductal injection of collagenase (Sigma of the pancreas and the fasting of the recipient rats 3 h prior to an intravenous glucose tolerance test (IVGTT).
Blend F, Sigma). After removing the pancreas from the rat, the tissue was digested and a series of washes in All experimental procedures were performed in an AAALAC-approved vivarium following Institutional Hanks balanced salt solution (HBSS, Sigma) supplemented with 15 mM HEPES (Gibco, Carlsbad, CA) was Animal Care and Use Committee guidelines. performed. The resulting islets were then coated with polyethylene tubing (PE90, Cardinal Health) and transplanted into one of the three sites. The islets that were bovine serum albumin (BSA, Sigma) and spun on a discontinuous dextran (Sigma) density gradient. The islets transplanted into the subcutaneous space were injected using one of the following techniques: injected into the were removed from the gradient and subjected to a final series of washes in HBSS with HEPES. The islets were tissue between the muscle and the skin using a 25-gauge butterfly or the skin and the subcutaneous tissue was cultured for 48 h at 22°C and 5% CO 2 in Medium 199 (Sigma) supplemented with 0.5 ml of 100× nicotinomide teased open in a similar fashion as described for device insertion and PE90 tubing containing islets was then in-(Sigma), 0.5 ml of 50 mM IBMX (Sigma), 5 ml of antibiotic/antimycotic (Gibco), 5 ml of L-glutamine (Gibco), serted into the space for subsequent transplantation. In order to transplant the islets into the device an incision 5 ml of 1 M HEPES, and 10 ml of heat-inactivated fetal calf serum (Sigma). The medium was changed at 24 h. was made at the anterior end of the device. The obdurator in the device was slowly removed and the islets were After culture, the islets were washed in HBSS and handpicked for the purpose of transplantation.
injected into the void where the obdurator had been. A new sterile cap was then placed on the end of the device Islet Transplantation instead of the obdurator and the incision was closed. Blood samples were obtained from the tail vein of Thirty-four diabetic rats were implanted with syngeneic islets and were divided into three groups [islets the animals three to five times per week and analyzed using an Accuchek Advantage glucometer (Roche Diag-transplanted either underneath the kidney capsule (13), into the subcutaneous space, or into a subcutaneous im-nostics, Indianapolis, IN). Normalization was determined to have occurred when an animal exhibited two planted device]. The objectives of the study were to determine whether the islets transplanted either in the sub-consecutive glucose levels below 200 mg/dl. Blood draws were decreased in frequency to once a week after an cutaneous space alone or in the device would support islet engraftment and function in a similar manner as animal normalized. The transplanted graft was harvested after 60 days in islets transplanted beneath the kidney capsule.
Each diabetic recipient received islet grafts roughly most cases. If normalization had occurred, the animal was anesthetized and the graft was removed for analysis. equivalent to 10 islets (>100 µm diameter) per gram. The hand-picked islets were aspirated using either a 25-
The incision was closed and the animal was monitored for the next 3-5 days to confirm reversion to the previ-gauge butterfly (Abbot Laboratories, Chicago, IL) or ous diabetic state (defined as two consecutive blood glu-oxidase. The primary antibodies consisting of mouse anti-human insulin monoclonal antibody (2 D11-HS, cose readings above 350 mg/dl). In most cases, if normalization did not occur the animal was euthanized and Novacastra, Newcastle upon Tyne, England) were applied to the slide after rinsing and then the slide was the graft was removed for analysis. However, some animals were used to evaluate the efficacy of a second incubated for 32 min at 37°C. The slide was then rinsed and rabbit anti-mouse IgG heavy and light chains anti-transplant.
Animals receiving subcutaneous devices that did not body was applied and incubated for 8 min at 37°C. After washing the slide, mouse anti-rabbit IgG was applied demonstrate glucose levels less than 200 mg/dl after 60 days received a second transplant into the lumen of the and incubated for 8 min at 37°C. After rinsing the slide, the biotinylated secondary antibody was applied and in-device. In these cases, an incision was made at the superior end of the device and the top of the device was cubated for 32 min at 37°C. The slide was then washed and streptavidin-enzyme conjugate added and incubated exposed. The cap was removed and a 25-gauge needle was used to create a space for the polyethylene tubing for 8 min at 37°C. The slide was then washed and the chromogenic enzyme substrate was added and incubated containing the islets. The islets were injected, the cap was placed on the end of the device, and the incision for 8 min at 37°C. Slides were evaluated using a Nikon Optiphot-2 mi-was closed. The animals were monitored as described above and the graft was harvested 30 days later and pro-croscope and the images captured using a Sony DXC-S500 CCD camera connected to a PC using the Kodak cessed for histology (see below).
Imaging for Windows software.
Intravenous Glucose Tolerance Test (IVGTT)
Statistical Analysis An IVGTT was performed on the animals that nor-Means and SDs were calculated for all data, and a malized and/or received a second transplant of islets.
Student's t-test, an analysis of variance (ANOVA), chi-Each of these animals was anesthetized with isoflurane square test, and a Kaplan Meier Survival curve was caland given a tail vein injection of 0.75 g glucose/kg. culated using Prism GraphPad 4.0 (Carlsbad, CA). Dif-Blood was drawn via tail vein at time 0, 5, 10, 15, 30, ferences were deemed significant at a 95% confidence 60, 90, and, in some cases, 120 min (time points 0, 5, level (p < 0.05). 10, and 15 were drawn while the animal was anesthetized). The glucose readings were graphed using Micro-RESULTS soft Excel and the K value calculated using the logarith-Normalization Days mic curve of the line [K = (ln2/T 1/2 ) × 100, where T 1/2 is the time of the half-maximum value of blood glucose Nine out of 12 (75.0%) animals became normoglycemic following renal subcapsular islet transplantation. derived from the glucose response curve].
In contrast, the subcutaneous space supported islet grafts Histology only when the islets were placed into the previously implanted device. Eight of 11 (72.7%) animals normalized Explanted devices were immediately fixed by placing them into Z-fix (zinc sulfate, Anatech, Battle Creek, in the device group while 0 of 12 (0%) normalized in the unprepared subcutaneous transplant group. Kaplan NJ) formalin. In order to remove the tissue from the device, a rotary cutting tool (Dremel, WI) with an abra-Meier curves for the day of normalization confirmed that the time to normalization was equivalent for the kid-sive cut off wheel attachment was used to section longitudinally along the stainless steel mesh. The mesh was ney capsule and subcutaneous device groups (Fig. 2a ).
Using the chi-square test, there was no statistical differ-peeled back and the tissue was removed using tweezers. The extracted tissue was cut into sections. Smaller sec-ence between the kidney transplant and the device groups (p = 0.653) for day of normalization (10.1 ± 5.2 kidney; tions were placed into paraffin. Additional 4-5-µm sections were cut and subjected either to hematoxylin and 13.8 ± 8.5 device), but both of these groups had significant outcomes compared to the subcutaneous transplant eosin staining (H&E) or to immunohistochemistry for the detection of insulin.
group (p = 0.0002). Figure 2b is a survival curve of the total length of time for the kidney and device groups Immunohistochemistry was performed using a conventional streptavidin-biotin enzyme conjugate method. that remained normoglycemic. There was no statistical difference in the overall time of normoglycemia between Briefly, 4-µm sections were cut and rehydrated and then placed in APK wash buffer. Immunohistochemistry was these two groups (p = 0.897). Figure 3 presents the glucose concentrations of the animals that cured in the kid-performed using a semiautomated immunostainer (Ventana Medical System, Tucson, AZ). H 2 O 2 (1.1%) was ney ( Fig. 3a ) and the device (Fig. 3b ) groups. One of the animals in the device group reverted back to the dia-used for 4 min at 37°C to quench any endogenous per- Figure 2 . (a) Kaplan Meier survival curves of the percent of animals that became normoglycemic (both islets transplanted underneath the kidney capsule and into the subcutaneous device). There was no statistical difference in the normalization between these two groups (p = 0.653). (b) Kaplan Meir survival curve of animals remaining normoglycemic (both islets transplanted underneath the kidney capsule and into the subcutaneous device). All of the animals remaining out to 60 plus days had their graft-bearing tissue or device removed to determine if the animal reverted back to a diabetic state. There was no statistical difference between these two groups (p = 0.90). betic state 29 days after transplantation and received an state upon removal of the graft bearing kidney tissue or subcutaneous device (Fig. 3) . additional 500 islets within the device. This animal normalized again after 21 days and remained normogly-IVGTT cemic for an additional 15 days until it reverted to the diabetic state. Three additional animals in the device An IVGTT was performed on all animals after the primary transplant (except for the subcutaneous trans-group that did not cure received a second transplant of 1000 islets into the lumen of the device. One of the three plant group) once they had become normoglycemic. These data were compared to IVGTTs performed on normal animals became normoglycemic and remained so until the device was removed from the subcutaneous tissue female adult rats (Fig. 4) . Upon analysis of the equations of the curve, data were accepted only for glucose clear-(data not shown). This animal was considered to be a failed graft due to the inability of originally becoming ance curves that had an R 2 value greater than or equal to 0.95. Based on this criterion, only five of six normal normoglycemic after the first islet transplant. All animals that had normalized reverted back to a diabetic animals, three of six of the kidney, and three of five of Figure 3 . Glucose concentrations measured for both the animals with islets transplanted underneath the kidney capsule (a) and islets transplanted into the subcutaneous device (b). An animal with a measurement of greater than 200 mg/dl was considered to be diabetic. All animals that remained normoglycemic for greater than 30 days had their graft-bearing tissue or device removed in order to demonstrate that the animal would revert back to a diabetic state. One animal in the device group (DC7) became normoglycemic after 27 days post-islet transplant and remained normoglycemic 29 days. A second transplant of 500 islets was performed in this animal and the animal became normoglycemic for an additional 15 days.
the device group were deemed significant (Table 1) . tween the mesh wall and the obdurator. A robust vascular bed was present surrounding and infiltrating the When an ANOVA was performed on the remaining values, the rate of glucose disposal did not differ among stainless steel device with numerous blood vessels seen extending in a radial-like manner through the mesh and the three groups (Table 1 ; p = 0.71).
into the tissue within the device. Upon removal of all of Device Removal the devices from normoglycemic animals, a similar pattern was still evident macroscopically with a well-estab-Gross examination of the devices at the time of islet transplantation revealed a well-formed bed of tissue both lished vascular supply to the device and each device largely filled with a solid mass of tissue. Histological surrounding the device and within the space created be- examination performed on sections of the surrounding cessful subcutaneous islet transplant group examined in this study. and infiltrating tissue revealed that the establishment of this vascular bed occurred only in those animals receiv-DISCUSSION ing the devices (Fig. 5a, b) . A similar vascular bed was not observed in the subcutaneous transplant site(s) (Fig. These experiments demonstrate for the first time that a device, inserted into the subcutaneous tissue of a rat 5c). Examination of the tissue inside the implanted devices demonstrated a vascularized tissue containing abun-to provide a preconditioned location for islet cell transplantation, supports islet engraftment and functions as dant areas of insulin positive beta cells ( Fig. 6b-e ), which was similar to islets transplanted underneath the kid-effectively as does the standard renal subcapsular site. Islet survival was not observed in any of the subcutane-ney (Fig. 6a) . Figures 5 and 6 are representative of all of the successful islet engraftment animals and nonsuc-ous transplants without the device. Glucose tolerance testing confirmed that the islets responded normally to graft site without any indication of inflammation within the transplanted tissue. Importantly, the benefits of the a bolus of glucose. The islets remained viable for 60 days postengraftment (the longest point examined) and subcutaneous device occurred in the majority, but not all, of the recipients. well-granulated beta cells were identified within the An ideal clinical outcome would be 100% successful 15). Further studies are needed to evaluate whether this device functions in a similar manner to create a vascu-islet engraftment and function within the device structure. In this study only 73% of the animals in the device larized local environment to support cellular engraftment. Future research will focus on demonstrating that group normalized. Nonetheless, the numbers of animals that normalized was comparable to animals receiving is-this device does create an organized vascular pedicle and identifying the time course of the creation of the lets beneath the kidney capsule. The few graft failures may have been a consequence of the formation of a cur-vascular bed. In addition, other studies will focus on characterizing the vascular flow established within the rently unidentified tissue surrounding the stainless steel mesh that prevented the formation of a vascular pedicle, device and its correlation to successful islet engraftment, subsequently comparing this to the native pancreas. an inflammatory response to the transplanted islets, or the failures may have been a function of the quality of Studies are currently under way to determine the rate of penetration of the vascular pedicle to the center of the the islets. Future studies should carefully examine the inflammatory response of the host to the graft as well as device. The current device design leaves slightly more than a 1-mm gap between the obdurator and the inner the formation and function of the vasculature infiltrating these devices.
wall of the stainless steel mesh. From our data, we noted that tissue forms within this gap. Hence, after removal The establishment and maintenance of a vascular bed is crucial for the initial engraftment and long-term func-of the obdurator, the internal volume available for islet transplantation is approximately 0.25 ml with a 2-3-mm tion of transplanted islets. A potential mechanism for how this device functions is that the stainless steel mesh inner diameter. Islets located in the center of this volume would require a vascular bed to bridge a distance of ap-induces a mild inflammation leading to hypervascularity with (in most cases) little fibrosis. Previous work in our proximately 1 mm in a short period of time in order to support the nutritional and oxygen demand of these laboratory with the subcutaneous implantation of foreign biomaterials (porous alginate beads) has demonstrated cells. In the current study, even though islets were transplanted as a packed volume, the entire volume of the that the fibrotic capsule that forms in response to the material creates a vascular bed that can support cellular device was not used for cell transplantation. This may have allowed the islets to redistribute along the perime-engraftment without a severe inflammatory response (7,
